RANKL

This MedLibrary.org supplementary page on RANKL is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Tumor necrosis factor (ligand) superfamily, member 11
PDB rendering based on 1s55.
Available structures: 1s55
Identifiers
Symbols TNFSF11; ODF; CD254; OPGL; RANKL; TRANCE; hRANKL2; sOdf
External IDs OMIM: 602642 MGI: 1100089 HomoloGene: 2744
RNA expression pattern

More reference expression data
Orthologs
Human Mouse
Entrez 8600 21943
Ensembl ENSG00000120659 ENSMUSG00000022015
Uniprot O14788 Q059M3
Refseq NM_003701 (mRNA)
NP_003692 (protein)		 NM_011613 (mRNA)
NP_035743 (protein)
Location Chr 13: 42.03 - 42.08 Mb Chr 14: 77.01 - 77.04 Mb
Pubmed search [1] [2]


RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor) is a molecule important in bone metabolism. This natural and necessary surface-bound molecule activates osteoclasts, cells involved in bone resorption. Overproduction of RANKL is implicated in a variety of degenerative bone diseases, such as rheumatoid arthritis and osteomyelitis.

RANKL also has a function in the immune system, where it is expressed by T helper cells and is thought to be involved in dendritic cell maturation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of the RANKL gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.[1]

See also

References

  1. ^ "Entrez Gene: TNFSF11 tumor necrosis factor (ligand) superfamily, member 11".

Further reading

  • Whyte M (2006). "The long and the short of bone therapy". N Engl J Med 354 (8): 860–3. doi:10.1056/NEJMe068003. PMID 16495400.  link
  • Buckley KA, Fraser WD (2003). "Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers.". Ann. Clin. Biochem. 39 (Pt 6): 551–6. PMID 12564836. 
  • Jeffcoate W (2005). "Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?". Diabetologia 47 (9): 1488–92. doi:10.1007/s00125-004-1477-5. PMID 15322748. 
  • Collin-Osdoby P (2005). "Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.". Circ. Res. 95 (11): 1046–57. doi:10.1161/01.RES.0000149165.99974.12. PMID 15564564. 
  • Whyte MP, Mumm S (2005). "Heritable disorders of the RANKL/OPG/RANK signaling pathway.". Journal of musculoskeletal & neuronal interactions 4 (3): 254–67. PMID 15615493. 
  • Clohisy DR, Mantyh PW (2005). "Bone cancer pain and the role of RANKL/OPG.". Journal of musculoskeletal & neuronal interactions 4 (3): 293–300. PMID 15615497. 
  • Anandarajah AP, Schwarz EM (2006). "Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.". J. Cell. Biochem. 97 (2): 226–32. doi:10.1002/jcb.20674. PMID 16240334. 
  • Baud'huin M, Duplomb L, Ruiz Velasco C, et al. (2007). "Key roles of the OPG-RANK-RANKL system in bone oncology.". Expert Rev Anticancer Ther 7 (2): 221–32. doi:10.1586/14737140.7.2.221. PMID 17288531. 
  • Yogo K, Ishida-Kitagawa N, Takeya T (2007). "Negative autoregulation of RANKL and c-Src signaling in osteoclasts.". J. Bone Miner. Metab. 25 (4): 205–10. doi:10.1007/s00774-007-0751-2. PMID 17593489. 
  • Boyce BF, Xing L (2007). "Biology of RANK, RANKL, and osteoprotegerin.". Arthritis Res. Ther. 9 Suppl 1: S1. doi:10.1186/ar2165. PMID 17634140. 
  • McClung M (2007). "Role of RANKL inhibition in osteoporosis.". Arthritis Res. Ther. 9 Suppl 1: S3. doi:10.1186/ar2167. PMID 17634142. 

External links

v • d • e
Proteins: clusters of differentiation (see also list of human clusters of differentiation)
1-50
CD1 (a-c, 1A, 1D, 1E) - CD2 - CD3 (γ, δ, ε) - CD4 - CD5 - CD6 - CD7 - CD8 (a) - CD9 - CD10 - CD11 (a, b, c) - CD13 - CD14 - CD15 - CD16 (A, B) - CD18 - CD19 - CD20 - CD21 - CD22 - CD23 - CD24 - CD25 - CD26 - CD27 - CD28 - CD29 - CD30 - CD31 - CD32 (A, B) - CD33 - CD34 - CD35 - CD36 - CD37 - CD38 - CD39 - CD40 - CD41- CD42 (a, b, c, d) - CD43 - CD44 - CD45 - CD46 - CD47 - CD48 - CD49 (a, b, c, d, e, f) - CD50
51-100
CD51 - CD52 - CD53 - CD54 - CD55 - CD56 - CD57- CD58 - CD59 - CD61 - CD62 (E, L, P) - CD63 - CD64 - CD66 (a, b, c, d, e, f) - CD68 - CD69 - CD70 - CD71 - CD72 - CD73 - CD74 - CD79 (a, b) - CD80 - CD81 - CD82 - CD83 - CD84 - CD85 (a, d, e, h, j, k) - CD86 - CD87 - CD88 - CD89 - CD90 - CD91- CD92 - CD93 - CD94 - CD95 - CD97 - CD98 - CD99 - CD100
101-150
CD101 - CD102 - CD103 - CD104 - CD105 - CD106 - CD107 (a, b) - CD108 - CD109 - CD110 - CD111 - CD112 - CD113 - CD114 - CD115 - CD116 - CD117 - CD118 - CD119 - CD120 (a, b) - CD121 (a, b) - CD122 - CD123 - CD124 - CD125 - CD126 - CD127 - CD129 - CD130 - CD131 - CD132 - CD133 - CD134 - CD135 - CD136 - CD137 - CD138 - CD140b - CD141 - CD142 - CD143 - CD144 - CD146 - CD147 - CD148 - CD150
151-200
CD151 - CD152 - CD153 - CD154 - CD155 - CD156 (a, b, c) - CD157 - CD158 (a, d, e, i, k) - CD159 (a, c) - CD160 - CD161 - CD162 - CD163 - CD164 - CD166 - CD167 (a, b) - CD168 - CD169 - CD170 - CD171 - CD172 (a, b, g) - CD174 - CD177 - CD178 - CD179 (a, b) - CD181 - CD182 - CD183 - CD184 - CD185 - CD186 - CD191 - CD192 - CD193 - CD194 - CD195 - CD196 - CD197 - CDw198 - CDw199 - CD200
201-250
CD201 - CD202b - CD204 - CD205 - CD206 - CD207 - CD208 - CD209 - CDw210 (a, b) - CD212 - CD213a (1, 2) - CD217 - CD218 (a, b) - CD220 - CD221 - CD222 - CD223 - CD224 - CD225 - CD226 - CD227 - CD228 - CD229 - CD230 - CD233 - CD234 - CD235 (a, b) - CD236 - CD238 - CD239 - CD240CE - CD241 - CD243 - CD244 - CD246 - CD247- CD248 - CD249
251-300
301-350
v • d • e
Cytokines: Tumor necrosis factors
Tumor necrosis factor (ligand) superfamily
Cluster of differentiation

Wikipedia content modification information:

  • This page was last modified on 8 July 2008, at 03:05.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "RANKL".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.